Antibody Information
General Information of This Antibody
| Antibody ID | ANI0KOZFW |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Ispectamab |
|||||
| Organization | Celgene Corp. |
|||||
| Indication | Multiple Myeloma |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
MEVQLVESGGGLVQPGGSLRLSCAASGFNISAPGIHWVRQAPGKGLEWVGFINPAGGYTD
YADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDYIRQYWTYVLDYWGQGTLVT VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLFSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEL LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS REEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Light Chain Sequence |
MDIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVP
SRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFP PSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTL TLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Ispectamab debotansine [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible participants must be ≥18 with measurable relapsed/refractory MM and ECOG 0-1, excluding those with CNS involvement, recent transplants (auto≤3mo/allo≤6mo), active HBV/HCV/HIV, pregnancy/lactation, or GVHD immunosuppression, with additional protocol-specified criteria applying.
|
||||
| Administration Dosage |
CC-99712 will be administered via intravenous (IV) infusion.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04036461 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1, Multicenter, Open-label, Dose Finding Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
|
||||
| Primary Endpoint |
The trial evaluates safety through adverse event monitoring (42+ days post-treatment), determines Maximum Tolerated Dose (≤33% DLT rate in first cycle), and assesses Dose Limiting Toxicities within 28 days in relapsed/refractory multiple myeloma patients.
|
||||
| Other Endpoint |
Key efficacy endpoints include IMWG-defined Overall Response Rate, Time to Response, Duration of Response, Progression-Free Survival, and Overall Survival (all tracked up to 3 years). Pharmacokinetic parameters (Cmax, Tmax, AUC, CLT, Ctrough) and anti-drug antibody development are also evaluated throughout the 3-year study period.
|
||||
References